| Objective: Studies found that the growth and metastasis of entity tumor depend on formation of new vessels, and the proliferation of new vascular endothelial cell of tumor is 20~2000 times to normal tissue. CD105 also named Endoglin, which is a proliferation-associated cell membrane antigen of human vascular endotheliao cells, and which is a part of trans- forming growth factor-β(TGF-β) binding receptor complex and is essential for angiogenesis. CD105 always strongly expressed in blood vessels of tissues where neovascularisation occurs and tumor tissue. Our investigation mainly study the change of solubility part of CD-105 (S-CD105) in serum of breast cancer patients between pre- and post operation, and compare to breast benign tumor group and health control group, so to find the rule and to provide the evidence for diagnosis, evaluation of therapeutic efficacy and monitoring recurence and metastasis of breast cancer.Methods: we random selected 37 breast cancer patients (24 infiltrating ductal carcinoma, 13 infiltrating lobular carcinoma) who accepted hospitalization and treatment in the Forth Hospital of Hebei Medical University during March 2006 to June 2006, 1 patient with osseous metastasis after operation, and selected 10 patients with breast benign tumor (6 fibroadenoma of breast, 4 adenopathies tumor of breast), otherwise, we selected 10 health subjects as control group. We used ELISA to detect the value of S-CD105 in serum of breast cancer patients per and post operation (the interval is 30 days) and control group, then to compare the results. And we used immunity histochemistry ways to detect the expression of VEGF, c-erbB2, ER and PR of breast cancer tissue, and finished statistical analysis.Results: 1 The value of serum S-CD105 of breast cancer patients belong to per-operation group and post-operation group are 3.755±0.610ng/ml and 3.078±0.561ng/ml, respectively. The value of serum S-CD105 of breast benign tumor group and control group are 3.301±0.393ng/ml and 3.309±0.506ng/ml, respectively. The value of serum S-CD105 of per-operation group is obviously higher than that of post-operation group (P=0.000), and it is higher than which of breast benign tumor group and control group also (P=0.027, P=0.030), there is no difference among post-operation group, benign tumor group and control group (P=0.311).2 The breast cancer patients can be divided into three groups: the diameter is less than or equal to 2 centimeter group, which is more than 2 centimeter but less than or equal to 5 centimeter group, and which is more than 5 centimeter group by the diameter of primary tumor. The values of serum S-CD105 belong to them are 3.307±0.536ng/ml, 3.743±0.505ng/ml and 4.181±0.640ng/ml, respectively. The value of serum S-CD105 of tumor diameter is more than 5 centimeter group is obviously higher than which of tumor diameter is less than or equal to 2 centimeter group (P=0.009), there is no difference in other groups (P=0.065,P=0.054).3 The breast cancer patients can be divided into three groups: the axillary nodes metastasis is negative group, which is more than or equal to 1 but less than or equal to 3 group, and which is more than or equal to 4 group by the state of axillary nodes metastasis. The values of serum S-CD105 belong to them are 3.564±0.430ng/ml, 3.676±0.659ng/ml and 4.485±0.419ng/ml, respecyively. The value of serum S-CD105 of more than or equal to 4 group is obviously higher than which of the other groups (P=0.001,P=0.003), there is no difference in other groups (P=0.562).4 The breast cancer patients can be divided into stage I group, stage II group and stage III group by UICC TNM staging value (2003). The values of serum S-CD105 belong to them are 3.100±0.404ng/ml, 3.759±0.566ng/ml and 4.117±0.614ng/ml, respectively. The value of serum S-CD105 of stage II and stage III group is obviously higher than stage I group (P=0.036,P=0.007), there is no difference between stage II group and stage III group (P=0.144).5 The breast cancer patients can be divided into four groups: the expression of VEGF is negative group, which is (+) group, which is (++) group and which is (+++) group by the intensity of the expression of VEGF. The values of serum S-CD105 belong to them are 3.772±0.335ng/ml, 3.521±0.382ng/ml, 3.690±0.680ng/ml and 4.597±0.464ng/ml, respectively. The value of serum S-CD105 of the expression of VEGF is (+++) group is obviously higher than which of other groups(P=0.026,P=0.002,P=0.005). There is no difference among the expression of VEGF is (-),(+),(++) group (P=0.638).6 The breast cancer patients can be divided into two groups: the (-) group and the (+) group, respectively, which by the intensity of the expression of ER, PR and c-erbB2. The values of serum S-CD105 belong to expression of ER is (-) group and (+) group are 3.690±0.558ng/ml, 3.791±0.645ng/ml, respectively. There is no difference between them (P=0.636). The values of serum S-CD105 belong to expression of PR is (-) group and (+) group are 3.748±0.597ng/ml, 3.760±0.632ng/ml, respectively. There is no difference between them (P=0.953). The values of serum S-CD105 belong to expression of c-erbB2 is (-) group and (+) group are 3.653±0.375ng/ml, 3.768±0.635ng/ ml, respectively. There is no difference between them (P=0.727).7 The breast cancer patients can be divided into the infiltrating ductal carcinoma group and the infiltrating lobular carcinoma group by the patho-staging standard of WHO (2003). The values of serum S-CD105 belong to them are 3.817±0.577ng/ml, 3.643±0.675ng/ml, respectively. There is no difference between them (P=0.415).8 The breast cancer patients can be divided into three groups, the histological grade I group, grade II group and grade III group by the histio-staging standard of WHO (2003). The values of serum S-CD105 belong to them are 3.337±0.539ng/ml, 3.828±0.616ng/ml and 4.141±0.207ng/ml, respectively. Altho- ugh there is no difference among them (P = 0.053), but following the raise up of histological grade, the value of serum S-CD105 has the tendency of raise up.9 The breast cancer patients can be divided into pro-menopausal group and menopausal group by the state of catamenia. The values of serum S-CD105 belong to them are 3.672±0.588 ng/ml and 3.812±0.632ng/ml, respectively. There is no differ- ence between them (P=0.501).10 In the test, the value of serum S-CD105 of a patient with osseous metastasis after operation 2 years is 7.377ng/ml, which is the highest value of the test group, and which obviously higher than the average level post-operation patients.Conclusions: 1 The level of serum S-CD105 of breast cancer patients is significantly increased, and has statistical signify- cance compared with breast benign tumor and health people.2 The level of serum S-CD105 of breast cancer patients can decrease to normal level after operation for 30 days, and has statistical significance compared with which of pre-operation patients,and which indicates that the tumor tissue is the main source of the increased level of serum S-CD105.3 The level of serum S-CD105 of breast cancer patients is significantly increased accompanied with the primary tumor is bigger, the axillary lymph nodes metastasis is more and the TNM stage is progress. The increased level of serum S-CD105 of breast cancer patients indicates that the cancer is serious, and prognosis mala.4 The level of serum S-CD105 of breast cancer patients with strong expression of VEGF is increased significantly, which indicates that the level of serum S-CD105 in the same with VEGF may become the biological parameter concernded with tumor metastasis and prognosis.5 The level of serum S-CD105 of breast cancer patients has no relation with the expression of ER, PRand c-erbB2 in tissue of tumor, and has no relation with tumor pathology types, histological grade, and condition of menopausal status also.6 In the study, there is a patient who occred osseous metastasis two years after operation, whose level of serum S-CD105 is increased significantly. Although it has no statistical significance, the high expression of serum S-CD105 of breast cancer may indicate the metastasis of tumor, which needs further study. |
PDF Full Text Request